6 withdrawn. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 6 |
Follow Headache Disorders, Primary: new trials by email Literature Review of Headache Disorders, Primary trials Research Report on Headache Disorders, Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen - Migraine | Phase 2 | Withdrawn | Allodynic Therapeutics, Inc | 2025-01-31 | 2025-12-08 | |
| Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL Fremanezumab, Placebo - Cadasil, Migraine | Phase 2 | Withdrawn | Mayo Clinic | 2021-12-01 | 2022-02-28 | |
| 4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine 4-aminopyridine, Atenolol, Placebo - Vestibular Migraine, Migraine Disorders | Phase 2 | Withdrawn | Massachusetts Eye and Ear Infirmary | 2019-01-01 | 2024-07-01 | |
| Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine IR-TPM (Topamax), XR-TPM (Trokendi XR) - Migraine, Headache | Phase 2 | Withdrawn | University of Minnesota | 2017-10-30 | 2019-11-01 | |
| DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study DP-VPA, DP-VPA Placebo - Migraine | Phase 2 | Withdrawn | D-Pharm Ltd. | 40 | 2008-07-01 | 2009-05-05 |
| Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine BGC20-1531, Lactose - Migraine | Phase 2 | Withdrawn | Boston Scientific Corporation | 2022-06-03 |
Migraine Disorders (6) · Headache (2) · Anxiety Disorders (1) · CADASIL (1) · Vestibular Diseases (1)
Brain Diseases (6) · Central Nervous System Diseases (6) · Headache Disorders (6) · Nervous System Diseases (6) · Pathological Conditions, Signs and Symptoms (3) · Neurologic Manifestations (2) · Pain (2) · Signs and Symptoms (2) · Brain Infarction (1) · Brain Ischemia (1) · Cardiovascular Diseases (1) · Cerebral Arterial Diseases (1) · Cerebral Infarction (1) · Cerebral Small Vessel Diseases (1)
4-Aminopyridine (1) · Acetaminophen (1) · Atenolol (1) · DP-VPA (1) · Lactose (1) · N-(4-(4-(5-methoxypyridin-2-yl)phenoxymethyl)-5-methylfuran-2-carbonyl)-2-methylbenzenesulfonamide (1) · Topiramate (1) · erenumab (1) · fremanezumab (1)
Allodynic Therapeutics, Inc (1) · Boston Scientific Corporation (1) · D-Pharm Ltd. (1) · Massachusetts Eye and Ear Infirmary (1) · Mayo Clinic (1) · University of Minnesota (1)
United States (3) · Denmark (1) · Israel (1) · Norway (1) · United Kingdom (1)
Annette C Toledano, MD (1) · Gilad Rosenberg, M.D. (1) · James F Meschia (1) · Messoud Ashina, MD (1) · Natalia Belikova, MD PhD (1) · Susan Marino, PhD (1)